The in Vitro Effects of Aprotinin on Twelve Different ACT Tests

Journal of Extra-Corporeal Technology

Volumn 36, Issue 1, 2004, Pages 51-57

  Jones, Karen ^a   Nasrallah, Fadi ^a   Darling, Edward ^a   Clay, Nicole ^a   Searles, Bruce ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Activated clotting time (ACT); Anticoagulation; Aprotinin; Cardiopulmonary bypass (CPB)

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; HEPARIN;

ADULT; ANTICOAGULATION; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC TEST; FUNCTION TEST; HEALTH CARE POLICY; HEPARINIZATION; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; STUDENT T TEST;

EID: 1642335430     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Mertzlufft F, Koster A, Hansen R, et al. Reliability of the heparin management test for monitoring high levels of unfractionated heparin: In vitro findings in volunteers vs. in vivo findings during cardiopulmonary bypass. Anesthesiology. 2000;92:1594-602.
2. Malviya S. Monitoring and management of anticoagulation in children requiring extracorporeal circulation. Seminar Thromb Hemost. 1997;23:563-7.
3. Stammers AH, Huffman S, Alonso A, et al. The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass. J ExtraCorp Technol. 1997;29:114-22.
4. Hill GE, Diego RP, Stammers AH, et al. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg. 1998;65:66-9.
5. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 1990;73:1119-26.
6. Amris CJ, Hilden M. Anticoagulant effects of trasylol: In vitro and in vivo studies. Ann NY Acad Sci. 1968;146:612-24.
7. Marx G, Pokar H, Reuber H, et al. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth. 1991;5:467-74.
8. Van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-5.
9. Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2(8571):1289-91.
10. Royston D, Bidstrup BP, Taylor KM, et al. Reduced blood loss following open heart surgery with aprotinin (trasylol) is associated with an increase in intraoperative activated clotting time (ACT). J Cardiothorac Anesthe. 1989;3:80.
11. Peters DC, Noble S. Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999;5:233-60.
12. Van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:788-97.
13. de Smet AAEA, Joen MCN, van Oeveren W, et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg. 1990;100:520-7.
14. Farooqi N, De Hert S, Vlaeminck R, et al. Effects of low doses of aprotinin on clotting times activated with celite and kaolin. Acta Anaesthesiolog Belgica. 1993;44:87-92.
15. Heiner J, Graham S, Darling E, et al. Reproducability and comparability of eight point of care ACT machines. J ExtraCorp Technol. (in press).
16. Despotis G, Filos KS, Levine V, et al. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg. 1996;82:1126-31.
17. Dietrich W, Dilthey G, Spannagal M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin- activated clotting time in heparin-pretreated patients undergoing open-heart surgery: A double-blind, placebo-controlled study. Anesthesiology. 1995;83:679-89.
18. Gibbs NM, Weightman WM, Thackray NM, et al. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. J Cardiothorac Vasc Anesthes. 1998;12:536-41.
19. Wang J-S, Lin C-Y, Hung W-T, et al. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Crdiovasc Surg. 1992;104:1135-40.
20. Wang J-S, Lin C-Y, Hung W-T, et al. Monitoring of heparin-induced anticoagulation with kaolin activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology. 1992;77:1080-4.
21. Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation. 1992;86:II-410-II-412.
22. Despotis GJ, Heinrich J, Joiner-Maier D, et al. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg. 1995;59:106-11.
23. Huyzen RJ, Harder MP, Gallandat Huet RCG, et al. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. J Cardiothorac Vasc Anesth. 1994;8:153-6.
24. Zucker ML, Walker C, Jobes D, et al. Comparison of celite and kaolin based heparin and protomine dosing assays during cardiac surgery: The in vitro effect of aprotinin. J ExtraCorp Technol. 1995;27:201-7.
25. Bode AP, Lust RM. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity. Thrombos Res. 1994;73:285-300.
26. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: Activated clotting time is reduced by binding of aprotinin to kaolin. Thorac Cardiovasc Surg. 1995;109:177-78.